GRANULES · NSE
Not in active coverage. Cited reporting has mentioned Granules India, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Granules India has submitted a Paragraph IV certification in connection with its Abbreviated New Drug Application for Ruxolitinib Extended-Release Tablets with respect to applicable patents listed with the US Food and Drug Administration.
This page lists where cited reporting has mentioned Granules India. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.